The research progress on immune checkpoint inhibitors is rapid, especially monoclonal antibodies targeting PD-1/PD-L1 and CTLA-4, which have been approved by the FDA for first-line treatment of melanoma and/or lung cancer. The gene discussed is PDCD1; the disease is lung carcinoma.